HEPATITE A
1- Gallian P, Barlet V, Mouna L, Gross S, Morel P, Le Cam S, Ricard C, Maugard C, Pouchol E, Flan B, Visse C, Djoudi R, Figoni J, De Valk H, Tiberghien P, Roque-Afonso AM. Persisting higher prevalence of hepatitis A virus RNA in blood donors, France, 2018. Euro Surveill. 2019 Nov;24(47):1900695
2-Izquierdo L, Mellon G, Buchaillet C, Fac C, Soutière MP, Pallier C, Dulioust A, Roque-Afonso AM.PLoS One. 2019 Jun 26;14(6):e0218482.Prevalence of hepatitis E virus and reassessment of HIV and other hepatitis virus seroprevalences among French prison inmates. Izquierdo L, Mellon G, Buchaillet C, Fac C, Soutière MP, Pallier C, Dulioust A, Roque-Afonso AM.PLoS One. 2019 Jun 26;14(6):e0218482.
3-Abi Nader E, Girard M, Leruez-Ville M, Sissaoui S, Lacaille F, Roque-Afonso AM, Debray Seroprevalence of Hepatitis E virus infection in children after liver transplantation: A single-center experience in France. D.Clin Res Hepatol Gastroenterol. 2020 Apr;44(2):174-180.
4-Guillaume M, Mouna L, Coustillères F, Lemée V, Roque-Afonso AM, Mourez T, Lefaucheur R. Invasive meningoencephalitis as the first manifestation of hepatitis A. .J Viral Hepat. 2019 Nov;26(11):1330-1333
5-Enkirch T, Severi E, Vennema H, Thornton L, Dean J, Borg ML, Ciccaglione AR, Bruni R, Christova I, Ngui SL, Balogun K, Němeček V, Kontio M, Takács M, Hettmann A, Korotinska R, Löve A, Avellón A, Muñoz-Chimeno M, de Sousa R, Janta D, Epštein J, Klamer S, Suin V, Aberle SW, Holzmann H, Mellou K, Ederth JL, Sundqvist L, Roque-Afonso AM, Filipović SK, Poljak M, Vold L, Stene-Johansen K, Midgley S, Fischer TK, Faber M, Wenzel JJ, Takkinen J, Leitmeyer K. Improving preparedness to respond to cross-border hepatitis A outbreaks in the European Union/European Economic Area: towards comparable sequencing of hepatitis A virus. Euro Surveill. 2019 Jul;24(28):1800397
6- Nicolay N, Le Bourhis-Zaimi M, Lesourd A, Martel M, Roque-Afonso AM, Erouart S, Etienne M, Ndeikoundam Ngangro N. A description of a hepatitis A outbreak in men who have sex with men and public health measures implemented in Seine-Maritime department, Normandy, France, 2017.BMC Public Health. 2020 Sep 22;20(1):1441
HEPATITE E
1- Marion O, Abravanel F, Izopet J, Kamar N. Failure to respond to ribavirin despite elevated intra-erythrocyte zinc level in transplant-patients with chronic hepatitis E virus infection. Transpl Infect Dis. 2019 Jan 21:e13050.
2- Marion O, Capelli N, Lhomme S, Dubois M, Pucelle M, Abravanel F, Kamar N, Izopet J. Hepatitis E virus genotype 3 and capsid protein in the blood and urine of immunocompromised patients. J Infect. 2019 Mar;78(3):232-240.
3- Marion O, Lhomme S, Abravanel F, Izopet J, Kamar N.Should 12 or 24 weeks post-ribavirin follow-up be considered to define sustained virological response in transplant-patients treated for chronic hepatitis E virus infection? Transpl Infect Dis. 2019 Mar 12:e13065.
4- Abravanel F, Goutagny N, Joffray R, Eichenlaub E, Baron S, Aversenq A, Bourg S, Mercier L, Larue Triolet A, Poirault D, Loubet M, Daniel S, Luciani F, Pothion C, Tourneur C, Dugua JM, Lhomme S, Izopet J. Performance characteristics of the VIDAS® ANTI-HEV IgM and IgG assays.J Clin Virol. 2019 Mar;112:10-14
5- Marion O, Lhomme S, Del Bello A, Abravanel F, Esposito L, Hébral AL, Lavayssière L, Cointault O, Ribes D, Izopet J, Kamar N. Monitoring hepatitis E virus fecal shedding to optimize ribavirin treatment duration in chronically infected transplant patients. J Hepatol. 2019 Jan;70(1):206-209.
6- Capelli N, Marion O, Dubois M, Allart S, Bertrand-Michel J, Lhomme S, Abravanel F, Izopet J, Chapuy-Regaud S.Vectorial Release of Hepatitis E Virus in Polarized Human Hepatocytes. J Virol. 2019 Feb 5;93(4).
7- S. Lhomme, F. Abravanel, N. Kamar, J. Izopet. Screening, diagnosis and risks associated with Hepatitis E infection. Expert Review of Anti-Infective Therapy 2019;17:403-418.
8- C. Diméglio, D. Kania, J. Mbombi Mantono, T. Kagoné, S. Zida, S. Tassembedo, A. Dicko, B. Tinto, S. Yaro, H. Hien, J. Rouamba, B. Bicaba, I. Medah, N. Meda, O. Traoré, E. Tuaillon, F. Abravanel, J. Izopet. Hepatitis E virus infections among patients with acute febrile jaundice in Burkina Faso. Viruses 2019;554:1-9.
9- J. Izopet, P. Trémeaux, O. Marion, M. Migueres, N. Capelli, S. Chapuy-Regaud, JM. Mansuy, F. Abravanel, N. Kamar, S. Lhomme. Hepatitis E virus infections in Europe. Journal of Clinical Virology 2019;120:20-26.
10- P. Gallian, E. Pouchol, R. Djoudi, S. Lhomme, L. Mouna, S. Gross, P. Bierling, A. Assal, N. Kamar, V. Mallet, AM. Roque-Afonso, J. Izopet, P. Tiberghien. Transfusion-transmitted hepatitis E virus infection in France. Transfusion Medicine Reviews 2019;33:146-153.
11- S. Lhomme, S. DebRoy, N. Kamar, F. Abravanel, D. Metsu, O. Marion, C. Dimeglio, SJ. Cotler, J. Izopet, H. Dahari. Plasma Hepatitis E Virus Kinetics in Solid Organ Transplant Patients Receiving Ribavirin. Viruses 2019;11:7.
12- S. Lhomme, P. Gallian, C. Diméglio, F. Abravanel, P. Tiberghein, J. Izopet. Viral load and clinical manifestations of hepatitis E virus genotype 3 infections. J Viral Hepatitis 2019;26:1139-1142.
13- IM. Sayed, L. Verhoye, C. Montpellier, F. Abravanel, J. Izopet, L. Cocquerel, P. Meuleman. Study of hepatitis E virus ORF2 antigen kinetics in human-liver chimeric mice and its impact on HEV diagnosis. Journal of Infectious Diseases 2019;220:811-819.
14- A. Del Bello, F. Abravanel, L. Alric, L. Lavayssière, S. Lhomme, J. Bellière, J. Izopet, N. Kamar. No evidence of occult hepatitis C or E virus infections in liver-transplant patients with sustained virological response after therapy with direct acting agents. Transplant Infectious Disease 2019;21:e13093.
15- A. Xhaard, AM. Roque-Afonso, V. Mallet, P. Ribaud, S. Nguyen-Quoc, PS. Rohrlich, R. Tabrizi, J. Konopacki, S. Lissandre, F. Abravanel, RP. Latour, A. Huynh. Hepatitis E and Allogeneic Hematopoietic Stem Cell Transplantation: A French Nationwide SFGM-TC Retrospective Study. Viruses 2019;11(7).
16- Protin, F. Abravanel, L. Alric, S. Tavitian, L. Obéric, J. Izopet, G. Martin-Blondel, L. Ysebaert. Ribavirin for chronic Hepatitis E virus infection in ibrutinib-exposed patients. Open Forum Infect Dis 2019;6:ofz345.
17- I.B. Olsoy, S. Henriksen, F.H. Weissbach, M. Larsen, K. Borgen, F. Abravanel, N. Kamar, E.J. Paulssen, H.H. Hirsch, C.H. Rinaldo. Seroprevalence of hepatitis E virus (HEV) in a general adult population in Northern Norway: the Tromso study. Med Microbiol Immunol, 2019, 208 :715-725
18- N. Capelli, M. Dubois, M. Pucelle, I. Da Silva, S. Lhomme, F. Abravanel, S. Chapuy-Regaud, J. Izopet. Optimized HEV culture and its application to measurements of HEV infectivity. Viruses 2020;12:1-11.
19- S. Lhomme, O. Marion, F. Abravanel, J. Izopet, N. Kamar. Clinical manifestations, pathogenesis and treatment of hepatitis E virus infections. Journal of Clinical Medicine 2020;9:1-25.
20- A. Yrondi, J. Salles, JM. Péron, M. Sporer, S. Taib, A. Gallini, C. Noilhan, C. Dimeglio, F. Entajan, M. Crequy, J. Izopet, L. Schmitt. The Prevalence of Hepatitis E in a Patient Cohort Presenting With Addictive Injection Behavior. Front Psychiatry. 2019;10:832.
21- L. Capai, N. Hozé, J. Chiaroni, S. Gross, R. Djoudi, R. Charrel, J. Izopet, S. Priet, S. Cauchemez, X. De Lamballerie, A. Falchi, P. Gallian. Seroprevalence and quantification of antibodies anti-HEV IgG among blood donors in Corsica, France, 2017. Eurosurveillance 2020; 25:pii=1900336.
22- H. Larrue, F. Abravanel, JM. Péron. Hepatitis E, what’s the real issue? Liver International 2020;Suppl 1:43-47.
23- S. Lhomme, F. Nicot, N. Jeanne, A. Roulet, C. Lefèbvre, R. Carcenac, M. Manno, M. Dubois, JM. Péron, L. Alric, N. Kamar, F. Abravanel, J. Izopet. Insertions and duplications in the polyproline region of the hepatitis E virus. Frontiers in Microbiology 2020;11:1.
24- F. Abravanel, C. Diméglio, M. Castanier, JM. Péron, N. Kamar, S. Lhomme, J. Izopet on behalf of the HEV study group. Does HEV-3 subtype play a role in the severity of acute hepatitis E? Liver International 2020;40:333-337.
25- N. Kamar, F. Abravanel, P. Behrendt, J. Hofmann, GP. Pageaux, C. Barbet, V. Moal, L. Couzi, T. Horvatits, RA. De Man, E. Cassuto, AM. Elsharkawy, A. Riezebos-Brilman, A. Scemla, S. Hillaire, MC. Donnely, S. Radenne, J. Sayegh, C. Garrouste, J. Dumortier, F. Glowaki, M. Matignon, A. Coilly, L. Figueres, C. Mousson, A. Minello, S. Dharancy, JP. Rerolle, P. Lebray, I. Etienne, P. Perrin, M. Choi, O. Marion, J. Izopet. Ribavirin for hepatitis E virus infection after organ transplantation: a large European retrospective multicenter study. Clinical Infectious Diseases 2020,;71:1204-1211
26- O. Marion, S. Lhomme, M. Nayrac, M. Dubois, M. Pucelle, M. Requena, M. Migueres, F. Abravanel, JM. Péron, N. Carrère, B. Suc, P. Delobel, N. Kamar, J. Izopet. Hepatitis E virus replication in human intestinal cells. Gut, 2020; 69:901-910
27- A. Belbézier, A. Deroux, F. Sarrot-Reynault, B. Colombe, A. Bosseray, C. Winternberger, P. Dumanoir, M. Lugosi, I. Boccon-Gibod, V. Leroy, M. Maignan, R. Collomb-Muret, D. Viglino, M. Vaillant, L. Minotti, E. Lagrange, O. Epaulard, C. Dumestre-Perard, S. Lhomme, J. Lupo, S. Larrat, P. Morand, C. Schwebel, A. Vilotitch, JL. Bosson, L. Bouillet. Screening of hepatitis E in patients presenting for acute neurological disorders. J Infect Public Health 2020;13:1047-1050.
28- S. Lhomme, F. Abravanel, M. Migueres, N. Kamar, J. Izopet. Hepatitis E virus: how to escape the host innate immunity? Vaccines 2020;8:E422.